Normal view MARC view ISBD view

TP53 in AML and MDS: The new (old) kid on the block. [Review] - 2023

MDS and AML are clonal hematopoietic stem cell disorders of increasing incidence, having a variable prognosis based, among others, on co-occurring molecular abnormalities. TP53 mutations are frequently detected in these myeloid neoplasms and portend a poor prognosis with known therapeutic resistance. This article provides a timely review of the complexity of TP53 alterations, providing updates in diagnosis and prognosis based on new 2022 International Consensus Classification (ICC) and World Health Organization (WHO) guidelines. The article addresses optimal testing strategies and reviews current and arising therapeutic approaches. While the treatment landscape for this molecular subgroup is under active development, further exploration is needed to optimize the care of this group of patients with unmet needs. Copyright © 2023 Elsevier Ltd. All rights reserved.


English

ISSN: 0268-960X

Standard No.: 10.1016/j.blre.2023.101055 [doi] S0268-960X(23)00016-4 [pii]

Subjects--Topical Terms:
*Leukemia, Myeloid, Acute
*Myelodysplastic Syndromes
*Myeloproliferative Disorders
Humans
Leukemia, Myeloid, Acute/di [Diagnosis]
Leukemia, Myeloid, Acute/ge [Genetics]
Leukemia, Myeloid, Acute/th [Therapy]
Mutation
Myelodysplastic Syndromes/di [Diagnosis]
Myelodysplastic Syndromes/ge [Genetics]
Myelodysplastic Syndromes/th [Therapy]
Prognosis
Tumor Suppressor Protein p53/ge [Genetics]--Automated

Index Terms--Occupation:
Hematology & Oncology Fellowship
MedStar Georgetown University Hospital/MedStar Washington Hospital Center

Index Terms--Function:
Journal Article
Review